RxDoctor Payments Data

Elizabeth Drake

Family · Winter Garden, FLNPI 1215451190

Payments from drug & device makers

$5,799in general payments, 2019–2025

Across 79 payments — averaging $73.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Draeger Medical Systems, Inc$4K
  • Novo Nordisk$726
  • Lilly USA, LLC$160
  • AbbVie$154
  • Johnson & Johnson$108
  • Sanofi-aventis U.S. LLC$88
  • plus $841 from 21 others

What the payments were for

  • Speaking & faculty fees$3,72064%
  • Food & beverage$2,07936%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,799 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$25,907
Medicare patients
110
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$147,951
OzempicSemaglutide67$88,250
JardianceEmpagliflozin66$87,491
FarxigaDapagliflozin Propanediol28$35,665
TrulicityDulaglutide11$29,045
RybelsusSemaglutide16$26,598
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$19,554
Tresiba Flextouch U-100Insulin Degludec17$13,364
Humalog Kwikpen U-100Insulin Lispro11$6,206
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$5,024
SynthroidLevothyroxine Sodium41$3,310
Ultra-Fine Short Pen NeedlePen Needle, Diabetic11$1,221
Levothyroxine Sodium76$703
Rosuvastatin Calcium26$540
Metformin Hcl ErMetformin Hcl45$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$160$176,995107 claims
Novo NordiskOzempic, Rybelsus$726$114,84983 claims
Boehringer IngelheimJardiance$18$87,49166 claims
AbbVieSynthroid$154$3,31041 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$64$70376 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Winter Garden

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →